Related Experiment Videos
Vascular restenosis - striving for therapy.
Thomas M Schiele1, Florian Krötz, Volker Klauss
1Ludwig-Maximilians-Universität München - Innenstadt, Department of Cardiology, University Hospital, Germany. Thomas.Schiele@medinn.med.uni-muenchen.de
Expert Opinion on Pharmacotherapy
|October 27, 2004
Summary
Restenosis after coronary angioplasty is a major problem. Drug-eluting stents show promise in preventing restenosis, offering a significant improvement over traditional methods.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- Restenosis, the re-narrowing of arteries after angioplasty, poses significant clinical and economic challenges.
- Conventional balloon angioplasty has high restenosis rates (30-60%), with coronary stenting reducing it by only ~30%.
Purpose of the Study:
- To review the pathophysiology, epidemiology, and predictors of restenosis.
- To evaluate various treatment options for preventing and managing restenosis.
Main Methods:
- Literature review of studies on coronary angioplasty, stenting, vascular brachytherapy, and drug-eluting stents.
- Analysis of incidence, morbidity, mortality, and cost associated with restenosis.
Main Results:
- In-stent restenosis affects ~250,000 patients globally annually, with high re-treatment rates.
- Vascular brachytherapy effectively reduces repeat in-stent restenosis by 50%.
- Drug-eluting stents demonstrate promising low restenosis rates (<10%) for both de novo and restenotic lesions.
Conclusions:
- Restenosis remains a critical issue in interventional cardiology.
- Drug-eluting stents represent a significant advancement in managing and preventing restenosis, particularly for high-risk patients.